Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28436555 | 0.80 | ESR1 (0.50) | ESR1S1PR1MAPTLMNARAB9A | |
| SCHEMBL6039803 | 0.78 | CA2 (0.46) | ESR1S1PR1MAPTLMNAL3MBTL1 | |
| SCHEMBL9822620 | 0.72 | PKM (0.45) | ESR1S1PR1TSHRKMT2AHTT | |
| SCHEMBL31048514 | 0.72 | CA2 (0.53) | L3MBTL1TSHRKMT2A | |
| SCHEMBL31048617 | 0.72 | RAB9A (0.38) | ESR1S1PR1MAPTLMNARAB9A | |
| SCHEMBL7230081 | 0.72 | ALDH1A1 (0.42) | ESR1S1PR1RAB9ATSHRKMT2A | |
| SCHEMBL3164442 | 0.70 | ESR1 (0.64) | ESR1S1PR1MAPTLMNARAB9A | |
| SCHEMBL21456938 | 0.70 | ESR1 (0.36) | ESR1S1PR1LMNARAB9AL3MBTL1 | |
| SCHEMBL11213747 | 0.70 | ESR1 (0.44) | ESR1S1PR1MAPTLMNARAB9A | |
| SCHEMBL7157659 | 0.69 | CA12 (0.47) | MAPTLMNAL3MBTL1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168165-A2 | TELOMERASE INHIBITOR COMPOUNDS | GERON CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3553061-A1 | NEW INHIBITORS OF BONE RESORPTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-16 | — | — | EP | disclosed |
| EP-3553061-A1 | NEW INHIBITORS OF BONE RESORPTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | TERT, POT1, TERF2 | ESR1 443/4885S1PR1 3570/4885MAPT 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.